Liver inflammation, a common side-effect of cancers elsewhere in the body, has long been associated with worse cancer outcomes and more recently associated with poor response to immunotherapy. Now, a team led by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania has found a big reason why.
Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
A new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies. Their study centers on a molecule called Jagged2, which plays a primary role in fueling the aggressiveness and immune evasion capacity of lung cancer.
Using spatial analysis of tissue samples, Cedars-Sinai investigators have identified patterns that could predict whether patients with the most common type of ovarian cancer will experience early relapse after treatment.
In patients undergoing colonoscopy to screen for colorectal cancer, deeper sedation using the anesthetic drug propofol may improve detection of "serrated" polyps — a type of precancerous lesion that can be difficult to detect, reports a study in the Online First edition of Anesthesiology, the peer-reviewed journal of the American Society of Anesthesiologists (ASA).
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN’s mission to help all people with cancer to live better lives.
New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.
Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone.
For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, reports a study in the April issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Researchers from the University of Michigan Health Rogel Cancer Center have created a urine-based test that detects pieces of DNA fragments released by head and neck tumors. The test could potentially facilitate early detection of this cancer type, which currently does not have a reliable screening method.
UWF faculty, serving as evaluators for Florida's Cancer Prevention and Control Program since 2018, recently had their contract renewed for $680,000 over four years due to excellent performance, as acknowledged by the CDC.
Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access to care among patients with metastatic castration-sensitive prostate cancer (mCSPC) since the first novel hormonal therapy was approved in 2018.
Researchers at Case Western Reserve University’s School of Medicine believe they have found information that could lead to developing new treatment options for people with metastatic colorectal cancer.
“Support is the most important part of cancer treatment,” says El Paso resident Rosario De Anda, who was diagnosed with breast cancer. “When I started to feel that sense of hope, I began to lose the fear. It made me want to live and push forward.” she adds.
For the study, which involved patients from across the world, Yale Cancer Center (YCC) researchers at Yale School of Medicine (YSM) analyzed the genetic landscape of 66 tumors, the largest series of cervical NET ever reported in scientific literature.
MD Anderson and CureVac today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
Smith is a nationally recognized academic radiologist with expertise in body and oncologic imaging, clinical trials and imaging research and the application of artificial intelligence (AI) in imaging and medicine.
Pesquisadores da Mayo Clinic criaram recentemente uma nova classe de algoritmos com inteligência artificial (IA) chamada IA orientada por hipóteses; se trata de um caminho alternativo dos modelos tradicionais de IA que aprendem apenas com dados.
Showing results
1–20 of 24670
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
